UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041

Benzinga · Sep 16 20:26

Once issued, this patent provides U.S. intellectual property coverage of UroGen's RTGel technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December 2041

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/535,108 entitled "Material and Method for Treating Cancer."

The allowed claims relate to the combination of UroGen's RTGel technology with medac's licensed proprietary lyophilized mitomycin formulation and cover the use of UroGen's UGN-103 and UGN-104 development programs in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and low-grade upper tract urothelial cancer (LG-UTUC), respectively. The U.S. patent, once issued, will have an expiration date in December 2041.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041

Risk Disclaimer